Audio player

Comments

Jeff Behrens, PhD - Why You're Wrong About Biotech Funding

Angel Invest Boston

Business

Join Sal Daher's Investment Syndicate: Click to Join Jeff Behren's doctoral dissertation suggests that life science startups are not funded the way we all think. Listen to our discussion of his work and learn why he believes we have to revise what is taught to founders about raising money. Highlights: Sal Daher Welcomes Jeff Behrens Back on the Podcast to Discuss His Findings on Biotech Funding “We published papers. We had a world class SAB, and ultimately, we sold these drugs. So, during that, you'd think, "Well, we should be able to raise venture capital." We never could.” The Conventional Wisdom about How Life Science Startups Are Funded Casma Therapeutics as an Example of a Startup Born Inside a Venture Firm “There was no Lisa and Joe… There [was] no outside founders. This was born inside the venture firm.” Jeff’s Research Result: Only 8% of All Startups Follow Path of Angel Funding Then VC Funding Jeff’s Research Result: For Biotech Startups, 4.5% of those that Started with Angel Money Got VC Funding “So, it's almost like these are two distinct entrepreneurial streams that don't intermingle very much.” Angel Investors Should Not Expect Future Rounds to Come from VCs – Should Think About How to Fund Future Rounds in the Absence of VC Money "Well, we want to have fewer new companies and more companies that we invest longer and heavier and over time." Jeff’s Research Result: In a Decade VC-Started Biotechs Went from Taking 20% of Funded Deals to Taking 80% The Big Biotech VCs Don’t Take Pitches from Outside Companies Anymore Only 3% Funding Goes to the Scrappy Biotechs Who Were Not VC-Founded or Did Not Have Famous Founders Scrappy Biotech Startups Need to Draw a Credible Path that Does Not Include VC Funding Corporate Venture Groups Created to Allow Big Players to Look at New Technologies Being Funded by a Corporate VC Does Not Seem to Increase the Chances of a Venture Being Acquired Trends Among Life-Science VCs Vary Geographically: Boston, NY vs. West Coast “We never take pitches” – Dave Berry - Partner - Flagship Pioneering Accelerators, Business Schools, Advisors Need to Revise their Ideas about Funding of Biotech Startups “So, it is true that Polaris is probably... Of these companies that are doing venture creation, they're probably more balanced than the others.” Path Dependency of Funding “…unfortunately, great science can languish unfunded.” Parting Thoughts from Jeff Behrens, PhD


More episodes  


Listen to Beth Marcus - Startup Doc

Beth Marcus - Startup Doc

Oct 28, 2020
Listen to Wade Lange - Startups at Purdue

Wade Lange - Startups at Purdue

Oct 21, 2020
Listen to Eilon Shalev - Elphi: Hacking Mortgages

Eilon Shalev - Elphi: Hacking Mortgages

Oct 7, 2020
Listen to Matt Fates, VC & Angel Investor

Matt Fates, VC & Angel Investor

Sep 30, 2020
Listen to David Glazer - Biotech Deal Wiz

David Glazer - Biotech Deal Wiz

Sep 23, 2020